AIM Immunotech Inc. annual report, FY2017

Full document

AIM Immunotech Inc. — 2017 Form 10-K Summary

Issuer identification: The supplied filing identifies the registrant as Hemispherx Biopharma, Inc. (NYSE American: HEB), not AIM Immunotech Inc. Verify the issuer/name mapping before relying on this summary.

Business context and reporting period

This is the annual report for the fiscal year ended December 31, 2017, filed March 29, 2018. Hemispherx was a clinical-stage specialty pharmaceutical company developing immune-system therapies. Its principal products were experimental Ampligen (rintatolimod) and Alferon N Injection, which was approved for a limited genital-warts indication but unavailable for commercial sale because the company lacked releasable finished inventory.

Financial results and liquidity

  • Revenue: $437,000, up from $92,000 in 2016. Revenue came from Ampligen clinical treatment and cost-recovery programs; there were no Alferon finished-goods sales.
  • Costs and losses: Total costs and expenses were $11.853 million, down from $13.896 million. Operating loss was $11.416 million; net loss was $8.259 million, compared with $7.502 million in 2016. Basic and diluted loss per share improved to $0.29 from $0.34.
  • Margins: The filing does not provide a meaningful commercial-product margin; reported revenue was small relative to operating expenses.
  • Cash flow: Operating activities used $7.941 million, versus $7.380 million in 2016. Investing activities provided $2.730 million and financing activities provided $4.215 million.
  • Cash and liquidity: At year-end, cash and cash equivalents were $1.412 million and marketable securities were $695,000, totaling $2.107 million. Working capital was $798,000, down from $4.506 million; total assets were $14.207 million.
  • Debt and equity: Year-end note payable was $1.835 million, net of discount, at a fixed 12% rate initially. Stockholders’ equity was $8.703 million, and accumulated deficit was $308.760 million. The company reported 32.885 million common shares outstanding at year-end.

Material changes versus 2016

  • Revenue increased by $345,000, largely due to the European early-access program for pancreatic cancer patients. Research and development expenses declined 20% and general and administrative expenses declined 14%, primarily reflecting cost reductions and the absence of a 2016 executive severance charge.
  • Net loss increased by $757,000. The filing attributes the change principally to lower gains from state tax-loss sales and no 2017 insurance settlement proceeds, partly offset by reduced operating expenses, higher Ampligen revenue, and a larger non-cash gain from warrant revaluation.
  • Cash and marketable securities declined by approximately $3.761 million. Shares outstanding increased from 24.203 million to 32.885 million, reflecting equity issuances and other share transactions.
  • At year-end, the company had drawn $1.9 million under a secured bridge facility. The note was paid off on March 16, 2018, alongside a transaction involving its New Jersey facility.

Outlook, risks, contingencies and unusual items

  • Ampligen regulatory path: The FDA’s 2013 Complete Response Letter required at least one additional clinical trial, nonclinical studies and data analyses. The company had not agreed with the FDA on the next study design and could not estimate the timing or cost; it said additional funding would be required. The FDA had cited insufficient evidence of efficacy and inadequate safety information in the submitted CFS application.
  • Commercialization: Argentina approved Ampligen for severe ME/CFS in 2016, but a launch still depended on reimbursement, marketing, manufacturing readiness and funding. The European early-access program included ME/CFS and pancreatic cancer; 34 pancreatic cancer patients had received treatment by year-end. Seventeen patients were participating in the U.S. AMP-511 open-label program.
  • Manufacturing: Alferon sales had been halted since 2008. Resumption required facility validation, an FDA pre-approval inspection and FDA release of new product; the filing estimated approximately $10 million would be needed to restart manufacturing and gave no definitive timetable. Jubilant’s first Ampligen lot was expected in the second quarter of 2018, subject to validation and release testing.
  • Funding and going concern: The company had a long history of losses, minimal product revenue and substantial financing needs. Management said actions including cost reductions and post-year-end financings and property transactions alleviated substantial doubt about continuing as a going concern. These actions do not remove the need for further capital; additional equity financing could dilute shareholders. No quantified operating guidance was provided.
  • Post-year-end financing and property transactions: In February 2018, the company sold an adjacent property for $1.05 million. In March, it received $1.26 million from warrant exercises and sold its manufacturing facility for $4.08 million while entering a 10-year leaseback and granting the buyer 3,225,806 warrants. The filing accounts for the facility transaction as financing because of the repurchase option; it is not presented as a completed accounting sale. The bridge note was repaid in connection with the transaction. The company also reported $475,000 net proceeds from a March stock offering.
  • Other contingencies: A March 2018 agreement resolved the company’s dispute with Nitto Avecia for a payment and additional consideration, but the amount was not stated. A separate supplier lawsuit against Biolife Plasma Services remained at an early stage, with no estimate of recovery. Other key risks include regulatory delay or rejection, product supply and manufacturing constraints, competition, and continuing need for capital.
  • Unusual accounting item: A $2.417 million non-cash gain from redeemable-warrant valuation affected 2017 results. The valuation used significant assumptions and Level 3 inputs.

Important facts for investors to verify

  • Confirm that this Hemispherx Biopharma filing is the intended filing for AIM Immunotech Inc.
  • Check current cash runway, subsequent financing, share count and potential dilution from warrants, options and the equity distribution agreement.
  • Verify the FDA’s current requirements and timing for Ampligen, and whether the anticipated manufacturing lot was validated and released.
  • Track the funding, inspection and approval steps needed to restart Alferon production, including the estimated restart cost.
  • Review the final Nitto Avecia settlement terms, the status of the Biolife litigation, and the accounting and obligations associated with the facility leaseback.